Drug Profile


Alternative Names: Alenia; Formoterol/budesonide; Symbicort; Symbicort pMDI; Symbicort SMART; Symbicort Turbuhaler

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biosintetica
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Aug 2017 AstraZeneca completes a phase III trial for Asthma (In children, In adolescents, In adults, In elderly) in Australia, New Zealand, Chile, Mexico, Peru, Bulgaria, Czech Republic, France, Germany, Hungary, Romania, Slovakia, Sweden, Spain, South Korea, Philippines, Thailand, Vietnam, South Africa, Russia, Ukraine, Saudi Arabia, Brazil, Colombia, Poland (NCT02224157)
  • 02 Aug 2017 AstraZeneca completes the phase III SYGMA 1 trial in Asthma (In adolescents, In adults) in Australia, Brazil, Bulgaria, Canada, Chile, China, Hungary, South Korea, Mexico, Peru, Philippines, Poland, Romania, Russia, South Africa, Ukraine, United Kingdom Vietnam (NCT02149199)
  • 27 Mar 2017 AstraZeneca completes a phase I bioavailability trial in Healthy volunteers in United Kingdom (Inhalation) (NCT02934607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top